Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. NYSE: LH. In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Labcorp stock on August 6th.
Representative April McClain Delaney also recently made the following trade(s):
- Sold $100,001 – $250,000 in shares of Wabtec NYSE: WAB on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Viking NYSE: VIK on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Trimble NASDAQ: TRMB on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Transdigm Group NYSE: TDG on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Tractor Supply NASDAQ: TSCO on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Middleby NASDAQ: MIDD on 8/25/2026.
- Sold $15,001 – $50,000 in shares of Teledyne Technologies NYSE: TDY on 8/25/2026.
- Sold $100,001 – $250,000 in shares of STERIS NYSE: STE on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Somnigroup International NYSE: SGI on 8/25/2026.
- Sold $100,001 – $250,000 in shares of Signet Jewelers NYSE: SIG on 8/25/2026.
Labcorp Price Performance
Shares of LH stock opened at $307.77 on Friday. The firm has a market cap of $24.96 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.82 and a beta of 0.88. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $341.80. The business’s 50 day moving average price is $309.90 and its 200-day moving average price is $281.74. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.
Labcorp (NYSE:LH – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The firm had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the previous year, the firm earned $4.35 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, equities research analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.
Labcorp Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is 23.82%.
Institutional Trading of Labcorp
A number of hedge funds have recently made changes to their positions in LH. California State Teachers Retirement System boosted its holdings in Labcorp by 28,952.8% in the second quarter. California State Teachers Retirement System now owns 35,002,800 shares of the medical research company’s stock worth $9,800,784,000 after acquiring an additional 34,882,320 shares in the last quarter. Victory Capital Management Inc. increased its stake in Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after purchasing an additional 2,719,475 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Labcorp by 1.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock valued at $607,241,000 after purchasing an additional 22,170 shares in the last quarter. Geode Capital Management LLC raised its holdings in Labcorp by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock worth $534,023,000 after buying an additional 13,775 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after buying an additional 289,029 shares in the last quarter. 95.94% of the stock is owned by institutional investors.
Insider Activity
In related news, EVP Kathryn Kyle sold 92 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the completion of the sale, the executive vice president owned 3,904 shares of the company’s stock, valued at $1,117,285.76. This trade represents a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Amy Summy sold 924 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the transaction, the executive vice president directly owned 6,956 shares in the company, valued at $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 8,919 shares of company stock valued at $2,826,593. Company insiders own 0.84% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on LH shares. Barclays raised their target price on shares of Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $306.00 price target on shares of Labcorp in a research note on Friday, July 31st. Mizuho set a $355.00 target price on Labcorp in a report on Monday, August 10th. JPMorgan Chase & Co. raised their target price on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Bank of America upped their price target on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $330.00.
Check Out Our Latest Analysis on LH
About Representative McClain Delaney
April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.
About Labcorp
Labcorp NYSE: LH, formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.
Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.
See Also
- Five stocks we like better than Labcorp
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Labcorp Right Now?
Before you consider Labcorp, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Labcorp wasn’t on the list.
While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
